Pui, C., Pei, D., Coustan-Smith, E., Jeha, S., Cheng, C., Bowman, W. P., Sandlund, J. T., Ribeiro, R. C., Rubnitz, J. E., Inaba, H., Bhojwani, D., Gruber, T. A., Leung, W. H., Downing, J. R., Evans, W. E., Relling, M. V., & Campana, D. (n.d.). clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet oncology, 16(4), 465–474. http://access.bl.uk/ark:/81055/vdc_100050890139.0x000028